Pharmacotherapy of obsessive-compulsive disorder: Experience with the selective serotonin reuptake inhibitors
Date
2000
Authors
Vythilingum B.
Cartwright C.
Hollander E.
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Since the introduction of the selective serotonin reuptake inhibitors (SSRIs) a decade ago, they have become first-line agents in the treatment of obsessive-compulsive disorder (OCD). Numerous clinical trials have confirmed their efficacy, and established their superior risk-benefit ratio in comparison with clomipramine, a non-selective serotonin reuptake inhibitor. Relatively higher doses and longer duration of treatment may be necessary to effect a response in OCD, with long-term treatment being required to maintain therapeutic gains. Despite the advances represented by the SSRIs, treatment resistance remains a problem. While no one solution exists, various strategies, including pharmacotherapy augmentation, look promising. (C) 2000 Lippincott Williams and Wilkins.
Description
Keywords
citalopram, clomipramine, fluoxetine, fluvoxamine, paroxetine, placebo, serotonin uptake inhibitor, sertraline, asthenia, clinical trial, conference paper, controlled clinical trial, controlled study, dose response, drug efficacy, drug half life, drug tolerance, gastrointestinal symptom, headache, human, insomnia, obsession, priority journal, psychopharmacotherapy, risk benefit analysis, tremor, xerostomia, Clinical Trials, Drug Resistance, Humans, Obsessive-Compulsive Disorder, Serotonin Uptake Inhibitors
Citation
International Clinical Psychopharmacology
15
SUPPL. 2
15
SUPPL. 2